Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ianalumab in Diffuse Cutaneous Systemic Sclerosis
NCT06470048Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2024
- Primary completion
- Jul 2027
- Countries
- 25
01
Overview
A Phase 2 trial of ianalumab in diffuse cutaneous systemic sclerosis (dcSSc), sponsored by Novartis. Started Oct 2024; status: active, not recruiting.
02
Drugs
ianalumab
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NCT06470048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06470048.